Payment overview · 2025
General Payments
$16,924.98
86 reported records · 14 companies
Healthcare provider profile · identity verified
Anne Webster, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PEORIA, IL · NPI 1124495379
Verified facts
What the public records show
CMS Open Payments records show Anne Webster, APN received $16,924.98 in general payments during 2025 across 86 reported records.
Abbott Laboratories accounted for 66.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Tymlos.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 799 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 630 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 1029 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $11,162.53 | 66.0% | 55 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $2,783.75 | 16.4% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $1,713.42 | 10.1% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$742.06 | 4.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $288.05 | 1.7% | 5 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $42.67 | 0.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.40 | 0.2% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $33.12 | 0.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.09 | 0.1% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $23.61 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.58 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.88 | 0.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $16.97 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.85 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $6,250.00 | 9 |
| Travel and Lodging | $5,511.13 | 23 |
| Consulting Fee | $3,000.00 | 1 |
| Food and Beverage | $2,099.31 | 51 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $11,066.53 | 41 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $2,765.68 | 3 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $2,765.68 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $1,713.42 | 7 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $734.96 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $96.00 | 14 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $42.67 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $33.12 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $7.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 630 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
799 | 145 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
630 | 124 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
229 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
1029 | 180 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 1029 | 180 |
| Jardiance | Empagliflozin | 799 | 145 |
| Metformin Hcl | Metformin Hcl | 779 | 179 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 639 | 173 |
| Mounjaro | Tirzepatide | 630 | 124 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 543 | 186 |
| Metformin Hcl Er | Metformin Hcl | 498 | 116 |
| Glipizide Er | Glipizide | 340 | 77 |
| Glipizide | Glipizide | 337 | 72 |
| Novolog Flexpen | Insulin Aspart | 300 | 90 |
| Tresiba Flextouch U-100 | Insulin Degludec | 283 | 76 |
| Glimepiride | Glimepiride | 236 | 54 |
| Trulicity | Dulaglutide | 229 | 42 |
| Humalog Kwikpen U-100 | Insulin Lispro | 202 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 52 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 187 | 55 |
| Januvia | Sitagliptin Phosphate | 181 | 34 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 179 | 24 |
| Tradjenta | Linagliptin | 177 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 147 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 146 | 36 |
| Gabapentin | Gabapentin | 124 | 29 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 114 | 48 |
| Farxiga | Dapagliflozin Propanediol | 108 | 22 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 102 | 18 |
| Novolog | Insulin Aspart | 95 | 25 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 92 | 36 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 87 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 20 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 75 | suppressed |
| Humalog | Insulin Lispro | 73 | 21 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 72 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 70 | 35 |
| Simvastatin | Simvastatin | 70 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 69 | 31 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 67 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 13 |
| Forteo | Teriparatide | 62 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 58 | 28 |
| Humalog Kwikpen U-200 | Insulin Lispro | 57 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 57 | 27 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 57 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | 18 |
| Levemir Flexpen | Insulin Detemir | 53 | 20 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 49 | 21 |
| Insulin Lispro | Insulin Lispro | 46 | 11 |
| Alendronate Sodium | Alendronate Sodium | 45 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Lisinopril | Lisinopril | 43 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 36 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 34 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 31 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 30 | 21 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Admelog Solostar | Insulin Lispro | 27 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 26 | 15 |
| Novofine 32 | Pen Needle, Diabetic | 25 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 23 | suppressed |
| Invokana | Canagliflozin | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 11 |
| Novolin N | Insulin Nph Human Isophane | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Teriparatide | Teriparatide | 19 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 18 | 11 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Tymlos | Abaloparatide | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Losartan Potassium | Losartan Potassium | 16 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 15 | 15 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,924.98 · 86 records | Abbott Laboratories | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 2, FREESTYLE LIBRE 3, INCEPTIV, INTELLIS ADAPTIVESTIM, MOUNJARO, Omnipod, RECORLEV, TWIIST, Tymlos, UNITHROID, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error